Association of Matrix Metalloproteinase-12 Polymorphisms with Chronic Obstructive Pulmonary Disease Risk: A Protocol for Systematic Review and Meta Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Aug 7

PMID 32756209

Citations 1

Authors

Hongjing Yang

Chuantao Zhang

Jianying Wu

Wei Xiao

Xiaohong Xie

Zhu Zeng

Keling Chen

Wujun Wang

Xing An

Wenjun Tang

Qingsong Huang

Affiliations

Soon will be listed here.

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a multifactorial disease with gene-environment interaction leading to airflow limitation through the respiratory tract. Reports on the association of matrix metalloproteinase 12 (MMP-12) polymorphisms with COPD have been controversial. A new systematic evaluation which could examine whether MMP-12 mutations are associated with the susceptibility to COPD is needed.

Methods: We will search PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure and Google Scholar to obtain eligible case-control studies for meta-analysis. The time is limited from the construction of the library to July 2020. Two investigators systematically will extract relevant data within those included studies.The odds ratio and 95% confidence intervals will be used to assess the genetic association between the allelic, dominant and recessive models of MMP-12 gene polymorphisms and COPD risk. Stata 12.0 software and Revman 5.3 will be adopted for statistical analysis. This protocol reported under the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses Protocols statement.

Results: This study will provide a better understanding of the association between MMP-12 polymorphisms and COPD risk.

Conclusion: Publishing this protocol will minimise the possibility of bias due to post hoc changes to the analysis protocol.

Citing Articles

Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease.

Christopoulou M, Papakonstantinou E, Stolz D Int J Mol Sci. 2023; 24(4).

PMID: 36835197 PMC: 9966421. DOI: 10.3390/ijms24043786.

References

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

Brozek G, Nowak M, Zejda J, Jankowski M, Lawson J, Pierzchala W . Costs of pharmacotherapy of chronic obstructive pulmonary disease in relation to changing Global Initiative for Chronic Obstructive Lung Disease guidelines (2007, 2011, and 2017 updates). Pol Arch Intern Med. 2019; 129(5):308-315. DOI: 10.20452/pamw.4487. View

Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C . Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018; 391(10131):1706-1717. DOI: 10.1016/S0140-6736(18)30841-9. View

Aggarwal T, Wadhwa R, Rohil V, Maurya P . Biomarkers of oxidative stress and protein-protein interaction in chronic obstructive pulmonary disease. Arch Physiol Biochem. 2017; 124(3):226-231. DOI: 10.1080/13813455.2017.1387796. View

Little J, Higgins J, Ioannidis J, Moher D, Gagnon F, von Elm E . STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009; 6(2):e22. PMC: 2634792. DOI: 10.1371/journal.pmed.1000022. View

Yu X, Zhang J, Zhao F, Pan X . Relationships of COX2 and MMP12 genetic polymorphisms with chronic obstructive pulmonary disease risk: a meta-analysis. Mol Biol Rep. 2014; 41(12):8149-62. DOI: 10.1007/s11033-014-3715-3. View

Joos L, He J, Shepherdson M, Connett J, Anthonisen N, Pare P . The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet. 2002; 11(5):569-76. DOI: 10.1093/hmg/11.5.569. View

Bchir S, Ben Nasr H, Garrouch A, Ben Anes A, Abbassi A, Tabka Z . MMP-3 (-1171 5A/6A; Lys45Glu) variants affect serum levels of matrix metalloproteinase (MMP)-3 and correlate with severity of COPD: A study of MMP-3, MMP-7 and MMP-12 in a Tunisian population. J Gene Med. 2017; 20(1). DOI: 10.1002/jgm.2999. View

Hogg J, Senior R . Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema. Thorax. 2002; 57(9):830-4. PMC: 1746435. DOI: 10.1136/thorax.57.9.830. View

10.

Gilowska I, Majorczyk E, Kasper L, Bogacz K, Szczegielniak J, Kasper M . The role of MMP-12 gene polymorphism - 82 A-to-G (rs2276109) in immunopathology of COPD in polish patients: a case control study. BMC Med Genet. 2019; 20(1):19. PMC: 6339316. DOI: 10.1186/s12881-019-0751-9. View

11.

Pillai S, Kong X, Edwards L, Cho M, Anderson W, Coxson H . Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182(12):1498-505. PMC: 3029936. DOI: 10.1164/rccm.201002-0151OC. View

12.

Ishii T, Angata T, Wan E, Cho M, Motegi T, Gao C . Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency. Respirology. 2016; 22(4):684-690. DOI: 10.1111/resp.12952. View

13.

May S, Li J . Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015; 36(1):4-10. PMC: 5554331. DOI: 10.2500/aap.2015.36.3812. View

14.

Haq I, Lowrey G, Kalsheker N, Johnson S . Matrix metalloproteinase-12 (MMP-12) SNP affects MMP activity, lung macrophage infiltration and protects against emphysema in COPD. Thorax. 2011; 66(11):970-6. DOI: 10.1136/thx.2011.159087. View

15.

Kabesch M, Adcock I . Epigenetics in asthma and COPD. Biochimie. 2012; 94(11):2231-41. DOI: 10.1016/j.biochi.2012.07.017. View

16.

Barnes P . New treatments for COPD. Nat Rev Drug Discov. 2002; 1(6):437-46. DOI: 10.1038/nrd820. View

17.

Demedts I, Morel-Montero A, Lebecque S, Pacheco Y, Cataldo D, Joos G . Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax. 2005; 61(3):196-201. PMC: 2080750. DOI: 10.1136/thx.2005.042432. View

18.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

19.

Haq I, Chappell S, Johnson S, Lotya J, Daly L, Morgan K . Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet. 2010; 11:7. PMC: 2820470. DOI: 10.1186/1471-2350-11-7. View

20.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View